Abstract
Controversies exist with regard to in vivo approaches to delayed immunologically mediated adverse drug reactions, such as exanthem (maculopapular eruption), drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and fixed drug eruptions. In particular, widespread differences exist between regions and practice on the availability and use of intradermal and patch testing, the standard drug concentrations used, the use of additional drugs in intradermal and patch testing to help determine cross-reactivity, the timing of testing in relation to the occurrence of the adverse drug reaction, the use of testing in specific phenotypes, and the use of oral challenge in conjunction with delayed intradermal and patch testing to ascertain drug tolerance. It was noted that there have been advances in the science of delayed T cell-mediated reactions that have shed light on immunopathogenesis and provided a mechanism of preprescription screening in the case of HLA-B*57:01 and abacavir hypersensitivity and HLA-B*15:02 and carbamazepine Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian subjects. Future directions should include the collaboration of large international networks to develop and standardize in vivo diagnostic approaches, such as skin testing and patch testing, combined with ex vivo and in vitro laboratory approaches.
| Language | English |
|---|---|
| Pages | 66-73 |
| Number of pages | 8 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 143 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2019 |
Cite this
Controversies in drug allergy : Testing for delayed reactions. / Phillips, Elizabeth J; Bigliardi, Paul; Bircher, Andreas J; Broyles, Ana; Chang, Yoon-Seok; Chung, Wen-Hung; Lehloenya, Rannakoe; Mockenhaupt, Maja; Peter, Jonny; Pirmohamed, Munir; Roujeau, Jean-Claude; Shear, Neil H; Tanno, Luciana Kase; Trubiano, Jason; Valluzzi, Rocco; Barbaud, Annick.
In: Journal of Allergy and Clinical Immunology, Vol. 143, No. 1, 01.2019, p. 66-73.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Controversies in drug allergy
T2 - Journal of Allergy and Clinical Immunology
AU - Phillips, Elizabeth J
AU - Bigliardi, Paul
AU - Bircher, Andreas J
AU - Broyles, Ana
AU - Chang, Yoon-Seok
AU - Chung, Wen-Hung
AU - Lehloenya, Rannakoe
AU - Mockenhaupt, Maja
AU - Peter, Jonny
AU - Pirmohamed, Munir
AU - Roujeau, Jean-Claude
AU - Shear, Neil H
AU - Tanno, Luciana Kase
AU - Trubiano, Jason
AU - Valluzzi, Rocco
AU - Barbaud, Annick
N1 - Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
PY - 2019/1
Y1 - 2019/1
N2 - Controversies exist with regard to in vivo approaches to delayed immunologically mediated adverse drug reactions, such as exanthem (maculopapular eruption), drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and fixed drug eruptions. In particular, widespread differences exist between regions and practice on the availability and use of intradermal and patch testing, the standard drug concentrations used, the use of additional drugs in intradermal and patch testing to help determine cross-reactivity, the timing of testing in relation to the occurrence of the adverse drug reaction, the use of testing in specific phenotypes, and the use of oral challenge in conjunction with delayed intradermal and patch testing to ascertain drug tolerance. It was noted that there have been advances in the science of delayed T cell-mediated reactions that have shed light on immunopathogenesis and provided a mechanism of preprescription screening in the case of HLA-B*57:01 and abacavir hypersensitivity and HLA-B*15:02 and carbamazepine Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian subjects. Future directions should include the collaboration of large international networks to develop and standardize in vivo diagnostic approaches, such as skin testing and patch testing, combined with ex vivo and in vitro laboratory approaches.
AB - Controversies exist with regard to in vivo approaches to delayed immunologically mediated adverse drug reactions, such as exanthem (maculopapular eruption), drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and fixed drug eruptions. In particular, widespread differences exist between regions and practice on the availability and use of intradermal and patch testing, the standard drug concentrations used, the use of additional drugs in intradermal and patch testing to help determine cross-reactivity, the timing of testing in relation to the occurrence of the adverse drug reaction, the use of testing in specific phenotypes, and the use of oral challenge in conjunction with delayed intradermal and patch testing to ascertain drug tolerance. It was noted that there have been advances in the science of delayed T cell-mediated reactions that have shed light on immunopathogenesis and provided a mechanism of preprescription screening in the case of HLA-B*57:01 and abacavir hypersensitivity and HLA-B*15:02 and carbamazepine Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian subjects. Future directions should include the collaboration of large international networks to develop and standardize in vivo diagnostic approaches, such as skin testing and patch testing, combined with ex vivo and in vitro laboratory approaches.
U2 - 10.1016/j.jaci.2018.10.030
DO - 10.1016/j.jaci.2018.10.030
M3 - Review article
VL - 143
SP - 66
EP - 73
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 1
ER -